Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.